Company Overview
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Why Investors Should Care
Revenue has grown at a 15.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $13.55M (+15.3% YoY); net profit $-25.32M.
- Trailing 12 Months Year-on-year growth — revenue +0.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 15.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.29% |
| 1 Year: | 0.30% |
Stock Price Performance
| 1 Year: | +47.17% |
| 6 Months: | +16.99% |
| 3 Months: | -16.69% |
| 1 Month: | -13.19% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 15.3% over 5 years.
CONS
- Trading 58.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CV CapsoVision, Inc. R2KPHARMA | 5.99 | -5.65 | $299.28M | 0.00% | - | - | 15.29% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 2.84M | 2.97M | 2.78M | 3.31M | 3.54M | 2.79M |
| Gross Profit | - | 1.59M | 1.66M | 1.49M | 1.81M | 1.91M | 1.33M |
| Operating Income | - | -5.27M | -5.80M | -5.38M | -4.65M | -8.02M | -7.09M |
| Net Income | -4.20M | -5.27M | -5.79M | -5.38M | -4.62M | -7.92M | -7.03M |
| Diluted EPS | - | -2.58 | -2.79 | -2.49 | -2.02 | -0.17 | -0.15 |
| R&D Expense | - | 4.22M | 4.52M | 3.11M | 3.39M | 6.09M | 4.43M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 11.76M | 13.55M |
| Gross Profit | 6.38M | 7.17M |
| Operating Income | -19.92M | -25.52M |
| Net Income | -19.90M | -25.32M |
| Diluted EPS | -9.85 | -1.03 |
| R&D Expense | 15.12M | 18.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 16.80M | 18.16M |
| Total Equity | -109.84M | -129.51M | 13.26M |
| Total Liabilities | - | 2.69M | 4.90M |
| Current Liabilities | - | 1.80M | 4.43M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -10.80M | -20.09M | -22.86M |
| Investing Cash Flow | -754.00K | -153.00K | -90.00K |
| Financing Cash Flow | 20.53M | 15.07M | 23.60M |
| Capital Expenditure | -754.00K | -153.00K | -90.00K |
| Free Cash Flow | -11.56M | -20.24M | -22.95M |
| Net Change in Cash | 8.97M | -5.17M | 650.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 54.2% | 52.9% |
| Operating Margin % | -169.4% | -188.3% |
| Net Margin % | -169.3% | -186.8% |
| ROE % | 15.4% | -190.9% |
| ROCE % | -132.8% | -185.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 3.79% | 1.90M | $11.24M |
| 2 | Vanguard Capital Management LLC | 2.11% | 1.06M | $6.28M |
| 3 | Geode Capital Management, LLC | 1.16% | 578.48K | $3.43M |
| 4 | State Street Corporation | 0.82% | 410.24K | $2.43M |
| 5 | Vanguard Portfolio Management LLC | 0.48% | 240.43K | $1.43M |
| 6 | Northern Trust Corporation | 0.44% | 220.09K | $1.31M |
| 7 | Vanguard Fiduciary Trust Co | 0.21% | 103.63K | $614.52K |
| 8 | Charles Schwab Investment Management, Inc. | 0.16% | 79.36K | $470.60K |
| 9 | Bank Of New York Mellon Corporation | 0.15% | 75.02K | $444.87K |
| 10 | Nuveen, LLC | 0.09% | 46.01K | $272.85K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CV
Should Value Investors Buy Vista Energy, S.A.B. de C.V. - Sponsored ADR (VIST) Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPQTR0NXdfV25rdVlFYnkzcDF2ZVVoMlVxcGtWbXVqVEFPX3NFSlNyTUxoZzNjejNNTmVrMWpOZ19WRWlfNVQ4SGFDN1FXSmFHZUtCR3ZsWFdCMWtsQjduMnp6VGcxZGhsQUFyOEVrdllnRG5YQ0I2ZExzUVdTSUdwQzVTSjNlQkZxYWFQeV…
NS Partners Ltd Decreases Stock Position in Vista Energy, S.A.B. de C.V. - Sponsored ADR $VIST - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPd3hrcXBKekpRNU1IeXJMdWIwaXhsSThteFhsLXF4UE1MUUx5VU5aMWNabnRsRVpsMmtMOUk1OU0wdkY0V0VkSVdISTJvcm4tYkotZGItWHc3M0VWTEFlZGdXTzYxY3JhcWNHMmVqU0xPazlDOVRDQmdHbTFaM29HdHpaRjdDa2p1VEhhNW…
CapsoVision (CV) Stock Rich Valuation Meets Widening Losses - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTFBOTU1BWTFoTUU5eXliMlJjVVVZMWd0eG9ncm5pc3lSbmloRzZBaGhsemU1SlBaVU1mUERaeEpUY1liQnlWbXdHWTYyTE1qbm1BLWd4S3AzUG4?oc=5" target="_blank">CapsoVision (CV) Stock Rich Valuation Meets Wide…
CAPSOVISION ($CV) Releases Q2 2026 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPOE81cUlEaTctOEY3azJ4WEQyeDQtWGprVnRQX0cyRXRqTHhWZ1VyWVozSHBLTEsxNDNjRFRCb01sT3Y1d1ZKTjJEVGVzLUNSYXMtYXR3Zi1WcmM2TTFocW0zTUE4Yl9teUhLVml1bE1TSDgtbnM4SmJTZFVsMHFsZThLOEpMTFdBeEE?oc…
Grupo Aeroportuario del Pacifico SAB de CV (PAC) Stock Down 3.4% -- Now Undervalued? GF Score: 92/100 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOQldwdnY3UGM2WS1oekF4YUxzX2dYSWY3aldLUVdXZmxLV01ydUFOUmlEbVFLbWpKc1RMbVBiSmN4a2wtX245Z2RWNGJUVnZSeXViSFY0dHJ6QmpCUER3SXRFRF9pWThyQTNnNWlOSVI5LWJHcDZXR2dqU3hTRjRwb3FNNHktRHRWSUt0T1…
CV Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1kYzA3Z0t1d1NQT0ZxZHBzOFFadUpMS2ZsWC1QNFVDOHptdERoYXlwRVVBZzA0VWxHWGdfMFNScy1KN3NVdVN3Rkl6WXFiV21fcUtBb0tIcHVFOWJBWjhLVDRTQkdIajRVZGRTRjdZXzg4clZmMi1v?oc=5" target="_blank">CV Fore…
CV — Frequently Asked Questions
What is the current share price of CapsoVision, Inc. (CV)?
As of 2026-09-07 16:24 PDT, CapsoVision, Inc. (CV) trades at $5.99 on NasdaqCM. Its 52-week range is $3.56 to $14.42.
What is the market capitalisation of CV?
CapsoVision, Inc. (CV) has a market capitalisation of $299.28M on NasdaqCM.
What is the P/E ratio of CV?
CV trades at a trailing price-to-earnings (P/E) ratio of -5.65. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 17.49.
Is CV a good stock to buy?
This page provides a data-driven analysis of CapsoVision, Inc. (CV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.